Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.

ManfredHauben; FerdinandoVegni; LesterReich; MuhammadYounus; (2007) Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis. European journal of gastroenterology & hepatology, 19 (11). pp. 934-941. ISSN 0954-691X DOI: 10.1097/MEG.0b013e3282efa502
Copy

OBJECTIVE: To compare reporting frequencies of hepatic adverse events between PEGylated and non-PEGylated formulations of active medicinal compounds in spontaneous reporting systems using a data mining algorithm (DMA). METHODS: Statistical DMAs are being promoted as a means of identifying drug-event combinations that are disproportionately reported in large spontaneous reporting systems databases, a critical data source for pharmacovigilance. After a review of case reports of hepatotoxicity with PEGylated drugs possibly associated with the polyethylene glycol moiety, we carried out a retrospective disproportionality analysis of WHO's multinational drug safety database for events related to hepatic dysfunction comparing PEGylated versus non-PEGylated formulations of four active moieties. A threshold of posterior interval (PI) 95% lower limit >0 was used to define a signal of disproportionate reporting with a drug and an event and 90% PIs of the information component were compared to identify statistical differences between the two compounds. RESULTS: On the basis of a total of 18 477 cases containing at least one of the drug pairs, we found disproportionate reporting for hepatic-related events with both PEGylated and non-PEGylated formulations. Overlapping of 90% PIs of the information components, however, suggested that there was no statistically significant difference between the frequency of hepatic injury reported with PEGylated versus non-PEGylated drug formulations. CONCLUSION: We did not find significant indicators of differential reporting of hepatic injury between PEGylated and non-PEGylated drug formulations in this exploratory analysis using one DMA. The analysis also suggests that comparative disproportionality methodology although not in itself determinative, could be one useful component of a risk management plan for monitoring the postmarketing experience of drug delivery systems that uses multiple methods and data streams.


Full text not available from this repository.

Explore Further

Read more research from the creator(s):

Find work associated with the faculties and division(s):

Find work from this publication: